AXSM Q4 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales

Axsome misses Q4 estimates for earnings. Revenues jump 65% on strong Auvelity sales as well as other product sales and top estimates.

Zacks Investment Research • 8 hours ago

Axsome Therapeutics, Inc. (AXSM) Q4 2025 Earnings Call Transcript

Axsome Therapeutics, Inc. (AXSM) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 23, 2026

Axsome: Q4 Earnings Review: Solid Performance, But Pipeline May Be Overvalued

Axsome Therapeutics, Inc. delivered 66% full-year 2025 revenue growth to $638.5M, driven by Auvelity and Sunosi, but remains loss-making. Despite a robust pipeline and upcoming catalysts, I downgrade AXSM to Hold due to valuation risks and commercial uncertainties in competitive markets. AXSM's 2030 revenue could reach ~$3.5B in a best-case scenario, but achieving blockbuster status for key assets like Sunosi and Symbravo remains uncertain.

Seeking Alpha • Feb 23, 2026

Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced financial results for the fourth quarter and full year 2025 and provided a general business update.

GlobeNewsWire • Feb 23, 2026

Here's What Key Metrics Tell Us About Axsome (AXSM) Q4 Earnings

The headline numbers for Axsome (AXSM) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Investment Research • Feb 23, 2026

Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates

Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.7. This compares to a loss of $0.96 per share a year ago.

Zacks Investment Research • Feb 23, 2026

Got $10,000? Axsome Therapeutics Could Be a Mental‑Health Moonshot by 2036

Axsome Therapeutics' lineup and late-stage pipeline could help drive strong sales growth for a while. The biotech won't run into patent cliffs in the near future, either.

The Motley Fool • Feb 22, 2026

AI, Clean Energy & Health Stocks: The Big Winners in a Multipolar 2026

NVIDIA, Albemarle and Axsome Therapeutics emerge as standout plays as AI, clean energy and healthcare draw massive capital in a split 2026 market.

Zacks Investment Research • Feb 20, 2026

Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd.

NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into a settlement agreement with Alkem Laboratories Ltd. (Alkem) resolving patent litigation related to Axsome's product SUNOSI® (solriamfetol). The litigation, which is pending in the United States District Court for the District of New Jersey, resulted from submission by Alkem of an Abbreviated New Drug Application to the U.S. Food and Drug Administration seeking approval to market a generic version of SUNOSI in the United States. Under the terms of the settlement agreement, Axsome will grant Alkem a license to sell its generic version of SUNOSI beginning on or after September 1, 2040, if pediatric exclusivity is granted for SUNOSI, or on or after March 1, 2040, if no pediatric exclusivity is granted, subject to FDA approval and conditions and exceptions customary for agreements of this type.

GlobeNewsWire • Feb 17, 2026

Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Should You Buy?

Axsome (AXSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Feb 16, 2026